-
Consistent generic drugs replace the original research supported by the top three! Will the country follow suit? The crisis of foreign enterprises is coming
Time of Update: 2018-07-19
The hospital, the direct user of the drug, unambiguously pointed out that "the drug should be tilted within the national policy framework through consistency evaluation", indicating that the follow-up
-
Another 16 varieties were listed on the public list, and 5 products were "exported for domestic sale"
Time of Update: 2018-07-19
Wonderful content on July 17, CDE official website released the public list of the 30th batch of drug registration applications to be included in the priority review procedure There are 16 varieties s
-
"God of medicine effect"! 12 more than 1 billion anti-tumor drugs are about to pass the consistency evaluation, and the price reduction trend of the original research drugs is coming?
Time of Update: 2018-07-17
Recently, the movie "I'm not the God of medicine" burst the circle of friends, causing a heated discussion among the whole people What's more exciting is that Jiangsu hausen has confirmed that it has
-
In depth analysis of the four potential anti-tumor drugs, can dominate the domestic market?
Time of Update: 2018-07-12
Under the promotion of multiple factors such as encouraging innovative drug policies, reducing import drug tariffs, giving priority to review and approval, and increasing prevalence, more and more imp
-
15 billion ADR market local pharmaceutical companies accelerate import substitution
Time of Update: 2018-07-09
According to data from the national health and Health Commission, the number of new born in 2016 reached 17.86 million, an increase of 7.92% over the previous year, forming a small peak According to a
-
These 13 domestic new drugs have obtained the qualification of FDA orphan drugs
Time of Update: 2018-07-06
These days, everyone is talking about the movie "I am not the God of medicine" In the film, the prototype of "Lenin" is Novartis' Gleevec (imatinib mesylate) The drug was first approved as orphan drug
-
Of the 1397 varieties reviewed, Pfizer, Novartis, GSK, China biopharmaceutical, etc. who declared the most?
Time of Update: 2018-07-05
CDE mid-2018 inventory: 1770 variety applications were undertaken and 1397 varieties were reviewed; Pfizer's 8 new application varieties ranked first in the application, followed by Novartis, GSK and
-
Analysis: Zhengda Tianqing ~ innovative drug R & D pipeline
Time of Update: 2018-07-03
Inscription Zhengda Tianqing Pharmaceutical Group, an innovative pharmaceutical group enterprise integrating scientific research, production and sales, is a well-known domestic research and developmen
-
Top 10, a best-selling oral drug, has been evaluated for consistency among four varieties! Which enterprises lead the way?
Time of Update: 2018-07-02
At present, there are 41 product specifications in the published 4 batches of drugs that have passed the consistency evaluation According to statistics, 289 kinds of essential drugs involve 17740 appr
-
Analysis: hausen pharmaceutical industry innovative drug R & D pipeline
Time of Update: 2018-06-29
Haosen Pharmaceutical Co., Ltd., founded in 1995, is a leading enterprise in research and development and production of anti-tumor and psychotropic drugs in China It ranks among the top 30 pharmaceuti
-
Lack of new antiepileptic drugs, less than 30% of domestic brands in 5 billion market
Time of Update: 2018-06-29
Epilepsy is one of the three major diseases of human central nervous system, and also one of the oldest and most typical diseases in history The incidence rate is even higher than that of Alzheimer's
-
The annual sales of urinary incontinence drugs is $3.4 billion, and the two varieties lead the domestic public hospital market
Time of Update: 2018-06-27
This week is the world urinary incontinence week, which was established by the International Association for urinary control in 2009 The time is from Monday to Friday at the end of June every year Acc
-
In the first half of the year, another four products were approved by the FDA, and the overseas business revenue of this pharmaceutical company exceeded one billion yuan
Time of Update: 2018-06-26
Highlights on June 20, humanwell pharmaceutical released a notice that Yichang humanwell Pharmaceutical Co., Ltd., a holding subsidiary, received the FDA approval number for bupropion hydrochloride su
-
Hengrui, Shiyao, LVYE, Zhengda Tianqing and other 30 class 1.1 innovative drugs have entered the third phase! How competitive is it?
Time of Update: 2018-06-21
Since this year, the innovation of local enterprises has continued to gain, and a number of innovative drug varieties that are favored by the outside world have been approved for listing, which makes
-
China's first local new hepatitis C drug has been approved for market, 5 pharmaceutical companies are fighting fiercely, Gilead's dominant position is dangerous
Time of Update: 2018-06-21
Recently, Geli announced on the official website that the company's first domestic new drug, danorevir sodium tablet (also known as danorevir sodium tablet, trade name: gonovi), which was originally r
-
Priority review + drug price negotiation! A new era of lung cancer treatment in China
Time of Update: 2018-06-19
The way of priority review has opened a green channel for these latest treatment schemes to enter the Chinese market Their coming implementation and application in China will bring good news to Chines
-
Domestic PD-1 drugs achieve zero breakthrough! Opdivo was approved, followed by MSD, Hengrui, Junshi, Xinda, etc
Time of Update: 2018-06-19
On June 15, the official website of the State Drug Administration issued the notice of approval of the listing of PD-1 antibody drugs, approving the injection of nevuliumab Injection (trade name: opdi
-
3-5 heavy-duty varieties with more than $1 billion are listed, and 20% of the sales come from overseas! "Golden decade" of innovative medicine?
Time of Update: 2018-06-15
Who will become the historical creator of Chinese innovative medicine entering the world?
-
New class 3 declaration is cold! Why are pharmaceutical companies not willing to invest?
Time of Update: 2018-06-15
Why injection declaration heat is significantly higher than oral medicine?
-
Rapid expansion of TiNi in 30 billion Lung Cancer Market: 40% of the leading varieties, what are the prospects of the two domestic new drugs?
Time of Update: 2018-06-14
On May 9, the class 1.1 innovative small molecule drug, androtinib hydrochloride capsule, independently developed by Zhengda Tianqing, obtained the registration approval and the trade name is fukewei